RANDOMIZED TRIAL OF RECOMBINANT GM-CSF FOR PATIENTS W/ ACUTE LUNG INJURY

重组 GM-CSF 用于急性肺损伤患者的随机试验

• 批准号: 7603750
• 负责人: Robert C Hyzy
• 金额: $ 0.16万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-03-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7603750
• 关键词: Acute Lung Injury; Adult Respiratory Distress Syndrome; Animals; Bacteria; Biological; Breathing; Cells; Cicatrix; Computer Retrieval of Information on Scientific Projects Database; Diagnosis; Enrollment; Funding; Future; Grant; Granulocyte-Macrophage Colony-Stimulating Factor; Healed; Infection; Institution; Life; Lung; Mechanical Ventilators; Patients; Pharmaceutical Preparations; Purpose; Randomized Controlled Clinical Trials; Recombinants; Research; Research Personnel; Resources; Source; United States Food and Drug Administration; United States National Institutes of Health; cancer therapy; cancer type; fight against; healing; injured; prevent; sargramostim

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Patients diagnosed with a life-threatening illness that has injured your lungs, called acute lung injury or Acute Respiratory Distress Syndrome (ARDS) who have been put on a mechanical ventilator, to help breathe, will be considered for enrollment in the study. The purpose of this study is to find out whether a drug called Sargramostim can help patients with acute lung injury or ARDS. Sargramostim is also known as GM-CSF. Sargramostim has been approved by the FDA to treat complications arising from some types of cancer or cancer treatment, and some studies using animals suggest that it may also help ARDS patients. Sargramostim is a biological compound that is already in the body, especially in the lungs. It is important for keeping lungs healthy. Sargramostim may help injured cells inside the lung heal faster, and it may help lungs fight against bacteria that can cause infections. It may also prevent or decrease scarring in the lungs. This study may help us develop better treatment for patients with ARDS in the future.'

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 被诊断患有危及生命的肺部损伤疾病（称为急性肺损伤或急性呼吸窘迫综合征（ARDS））并已使用机械呼吸机帮助呼吸的患者将被考虑入组本研究。这项研究的目的是发现一种名为沙格司亭的药物是否可以帮助急性肺损伤或ARDS患者。 沙格司亭也称为GM-CSF。 沙格司亭已被FDA批准用于治疗某些类型的癌症或癌症治疗引起的并发症，一些使用动物的研究表明，它也可能有助于ARDS患者。 沙格司亭是一种生物化合物，已经在体内，特别是在肺部。 这对保持肺部健康很重要。 沙格司亭可以帮助肺内受伤的细胞更快地愈合，它可以帮助肺部对抗可能导致感染的细菌。 它还可以预防或减少肺部的疤痕。 这项研究可能有助于我们在未来为ARDS患者开发更好的治疗方法。'